Spark Gets A Check From Pfizer And A Downgrade From Vetr

The Vetr crowd downgraded their rating for Spark Therapeutics Inc ONCE on Thursday, from 4.5 stars (Strong Buy), issued 519 days ago, to 4 stars (Buy). Crowd sentiment for Spark is primarily positive, with 80 percent of Vetr user rating bullish.

The genetic research company gained traction when it announced it would be receiving $15 million from Pfizer Inc. PFE after completing a successful safety and efficacy profile of a potential hemophilia therapy.

Responding to this news, share price in the stock shot up nearly $10 to peak just shy of the $60 mark. Spark ended the January 5 trading day a little lower at $58.68.

See how crowdourced ratings could help you time the market.

Currently, the Vetr crowd's average target price for Spark Therapeutics is up at $62.50, which is higher than the average analyst target price of $59.68. Less than 2 percent of Vetr users are holding ONCE in their watch lists.

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: BiotechDowngradesCrowdsourcingAnalyst RatingsVetr
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!